Frontiers in Psychiatry
January 23, 2024
Johannes Hauser, Jan Sarlon, Timur Liwinski et al.
10 citations
BackgroundAlthough the effectiveness of (es)ketamine for therapy-resistant depression (TRD) has been established, potential treatment-limiting factors include side effects like dissociation, anxiety, or elevated blood pressure. Music can reduce stress and negative emotions as anxiety. This study aimed to investigate the impact of listening to music during intranasal (es)ketamine administration...
International Clinical Psychopharmacology
January 22, 2024
L. Chevalier, Samuel Bulteau, L. Cheval et al.
Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted...
January 18, 2024
Esketamine has shown enhancements in processing speed, working memory, and verbal learning in adolescents with major depressive disorder and suicidal ideation. More studies are needed to determine esketamine dosing, its long-term side effects, and clinical benefits.
Canadian Journal of Health Technologies
January 17, 2024
Angela M. Barbara, Weiyi Xie, Quenby Mahood et al.
4 citations
What Is the Issue? Many drug treatments are available for depression, but 22% of people in Canada with the condition have treatment-resistant depression (TRD). For people with TRD, standard drug treatments do not improve their symptoms or do not work for long, and their depression persists. Posttraumatic stress disorder (PTSD) is a disabling mental health condition that affects about 9% of...
Journal of Affective Disorders
January 15, 2024
Yong Yang, Akifumi Eguchi, Xiayun Wan et al.
Depression is a frequent symptom in patients with chronic liver disease; however, the mechanisms underlying this association remain unclear. Dysbiosis of gut microbiota plays a critical role in depression through the gut-brain axis via the vagus nerve. In this study, we investigated whether the gut-microbiota-liver-brain axis plays a role in depression-like phenotypes in mice with hepatic...
Science Translational Medicine
January 10, 2024
Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu et al.
26 citations
How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....
Journal of Child and Adolescent Psychopharmacology
January 3, 2024
Alice Lineham, Victor J. Avila‐quintero, Michael H. Bloch et al.
15 citations
Objective:Ketamine has proved effective as a rapid-acting antidepressant agent, but treatment is not effective for everyone (approximately a quarter to a half of patients). Some adult studies have begun to investigate predictors of ketamine's antidepressant response, but no studies have examined this in adolescents with depression. Methods:We conducted a secondary data analysis of adolescents...
BMC Psychiatry
January 2, 2024
Minna Chang, Mario F Juruena, Allan H. Young
16 citations
Abstract Background Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although...
Telangana Journal of Psychiatry
2024
Pallavi Preetinanda, Srikrishna Nukala, Abhilash Garapati et al.
Treatment-resistant depression (TRD) is one of the most debilitating conditions that does not respond to conventional pharmacotherapy. Ketamine is a recently used effective treatment option in depressive disorders with a novel mechanism of action. Still, studies estimating the improvement of depressive symptoms in TRD with multiple doses of ketamine are limited. Hence, we report 5 TRD cases...
The Brown University Psychopharmacology Update
2024
A Phase 3b open‐label trial has found that esketamine nasal spray in combination with an antidepressant was more efficacious than extended‐release quetiapine plus an antidepressant in patients with treatment‐resistant depression. Both patient groups experienced improved remission rates over time.